Karyopharm Therapeutics (NASDAQ:KPTI) Given New $33.00 Price Target at Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target reduced by Royal Bank of Canada from $34.00 to $33.00 in a report released on Tuesday,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock.

Several other research firms have also commented on KPTI. HC Wainwright boosted their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. Barclays boosted their price target on shares of Karyopharm Therapeutics from $5.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Robert W. Baird reduced their price target on shares of Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.20.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $5.44 on Tuesday. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $17.85. The company has a 50-day moving average of $5.41 and a 200 day moving average of $8.79. The firm has a market capitalization of $46.62 million, a price-to-earnings ratio of -5.33 and a beta of 0.33.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Monday, May 12th. The company reported ($2.77) EPS for the quarter, beating the consensus estimate of ($4.21) by $1.44. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $35.12 million. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Velan Capital Investment Management LP purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $27,000. Focus Partners Wealth purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $31,000. TD Waterhouse Canada Inc. purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter worth approximately $32,000. Two Sigma Advisers LP grew its position in Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $85,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).